Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Blood (2025) 146 (Supplement 1): 5350.

https://doi.org/10.1182/blood-2025-5350

Published: 2025

Journal Articles

Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL

Laura Fogliatto, Ana Cordeiro, Eva Domingo Domenech, Daniel Morillo, Augustin Penedo Coello, Erika Bågeman, Danijela Lindahl, Ingrid Karlsson, Linda Mårtensson, Zinnia Parra Guillen, Dmytro Piliuhin, Karin Risberg Handeland, Ingrid Teige, Johan Wallin, Björn Frendeus, Andres McAllister

Blood (2025) 146 (Supplement 1): 5349.

https://doi.org/10.1182/blood-2025-5349

Published: 2025

Journal Articles

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Raul Cordoba, Maria Carmen Martinez Munoz, Rosa Maria Rodriguez Nunez, Blanca Sánchez-González, Miriam Moreno, Norma Gutiérrez, David Alonso Castronuño, Jimena Cannata, Pilar Gomez Prieto, Laurentino Benito, Tamara Torrado, Joan Buch, Juan Carlos Caballero, Nazaret Dominguez, Raquel Santiago Alonso, Isabel González-gascón-y-Marín, Maria Moya Arnao, Beatriz De La Cruz, Cecilia Carpio, Maria Dolores Gutiérrez-Meca Maestre, Luis Antonio López Gómez, Eukene Gainza, Maria Rocio Figueroa Mora, Paula Fernandez-Caldas, Mariana Bastos-Oreiro, Paola Villafuerte Gutiérrez, Samuel Romero Dominguez, Belen Navarro Matilla, Izaskun Zeberio, Emilia Pardal De La Mano, Antonio Gutierrez, Eva Donato, Javier Nuñez, Teresa Cobo, Begona Mendibil, Inigo Olazabal Eizaguirre, Maria Isabel Gomez Roncero, Cristina Barrenetxea, Haridian de la Nuez, Sara Ferrero, Roberto Trelles, Maria Garcia Roa, Luis Ignacio Sancho Val, Sofia Martin-Consuegra, Maria Luisa Bengochea, Carmen Alonso Prieto, Elena Ramila, Hugo Daniel Luzardo Henríquez, Maria Jesus Peñarrubia, Alfonso Ortiz, Ignacio Mahillo, Eva Domingo Domenech

Blood (2025) 146 (Supplement 1): 6264.

https://doi.org/10.1182/blood-2025-6264

Published: 2025

Journal Articles

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Kateryna Filonenko, Marco Picardi, Michal Kurlapski, Livio Trentin, Eva Domingo Domenech, Caterina Patti, Ramon Garcia-Sanz, Javier Nuñez Cespedes, Javier Lopez Jimenez, Agnieszka Giza, Stephane Chauvie, Davide Rossi, Andrea Riccardo Filippi, Maria Pirosa, Marta Bednarek, Anna Sureda Balarí, Alessandro Rambaldi, Andrea Gallamini, Jan Maciej Zaucha

Blood (2025) 146 (Supplement 1): 8243.

https://doi.org/10.1182/blood-2025-8243

Published: 2025

Journal Articles

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

Blood (2025) 146 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2025-3621

Published: 2025

Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Blood (2024) 144 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2024-212970

Published: 2024

Journal Articles

Predictive Value of Interim and End of Treatment PET/CT in Front-Line Treatment of Peripheral T-Cell Lymphoma

Nicolo Rampi, Belen Hervas Sanz, Carolina Esther Arevalo Leon, Angelo Castellani, Patricia Lopez Pereira, Elena Bechtold Javier, Ana C de Oliveira, Sara Pacella, Carmen Aguilera, Anna Valer, Eva Gonzalez Barca, Francesca Gaia Rossi, Carolina Martinez-Ramos, Ana Maria Sureda Balari, Montserrat Cortes-Romera, Eva Domingo Domenech

Blood (2024) 144 (Supplement 1): 6417.

https://doi.org/10.1182/blood-2024-210108

Published: 2024

Journal Articles

A Multicenter, Open-Label, Phase 3, Randomized Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients with Relapsed/Refractory Nodal T Cell Lymphoma with T Follicular Helper Phenotype

Kate Cwynarski, Eva Domingo Domenech, David Sidransky, Ohad S Bentur, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 3074.1.

https://doi.org/10.1182/blood-2024-203290

Published: 2024

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Ramon Garcia-Sanz, Anna Sureda Balari, Eva Domingo Domenech, Francisco Javier Capote Huelva, Antonio Gutierrez, Antonia Rodriguez Izquierdo, Marta Grande De Domingo, Lourdes Baeza

Blood (2024) 144 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2024-193585

Published: 2024

Journal Articles

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 460.

https://doi.org/10.1182/blood-2024-200992

Published: 2024

Journal Articles

Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Blood (2024) 144 (Supplement 1): 4947.

https://doi.org/10.1182/blood-2024-202933

Published: 2024

Journal Articles

Neurofilaments As Serum Biomarkers of Brentuximabvedotin-Induced Peripheral Neurotoxicity in CD30 + Lymphoma Patients: A Prospective Single-Center Study

Eva Domingo Domenech, Carla Marco, Eva Maria Gonzalez Barca, Cristina Muniesa, Patricia Lopez-Pereira, Ana C. De Oliveira, Carmen Aguilera, German Ferrer, Anna Maria Sureda Balari, Roser Velasco

Blood (2023) 142 (Supplement 1): 6186.

https://doi.org/10.1182/blood-2023-182348

Published: 2023

Journal Articles

Impact of Front-Line Treatment Interim PET/CT in Peripheral T-Cell Lymphoma Patients' Survival: Experience of a Single Center

Nicolo Rampi, Montserrat Cortes-Romera, Patricia Lopez-Pereira, Carolina Martinez-Ramos, Clara Montane Carbo, Carolina Esther Arevalo Leon, Ana C. De Oliveira, Eva Maria Gonzalez Barca, Anna Maria Sureda Balari, Eva Domingo Domenech

Blood (2023) 142 (Supplement 1): 6216.

https://doi.org/10.1182/blood-2023-186195

Published: 2023

Journal Articles

Comprehensive Geriatric Assessment in Diffuse Large B-Cell Lymphomas Patients Older Than 70 Years Old: Prospective Single-Center Experience

Nicolo Rampi, Maite Antonio, Eva Domingo Domenech, Patricia Lopez-Pereira, Ana C. De Oliveira, Carmen Aguilera, Anna Maria Sureda Balari, Eva Maria Gonzalez Barca

Blood (2023) 142 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2023-190136

Published: 2023

Journal Articles

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood (2023) 142 (Supplement 1): 302.

https://doi.org/10.1182/blood-2023-179304

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Blood (2023) 142 (Supplement 1): 611.

https://doi.org/10.1182/blood-2023-172574

Published: 2023

Journal Articles

Epigenetic loss of m 1 A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome

Blood (2021) 137 (7): 994–999.

https://doi.org/10.1182/blood.2020005823

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Nancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Amitkumar Mehta, Andres Forero-Torres, Ramon Garcia-Sanz, Philippe Armand, Sumana Devata, Antonia Rodriguez Izquierdo, Izidore S. Lossos, Craig Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, Andras Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

Blood (2020) 136 (21): 2401–2409.

https://doi.org/10.1182/blood.2019004701

Published: 2020

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Predictive Value of Interim and End of Treatment PET/CT in Front-Line Treatment of Peripheral T-Cell Lymphoma

A Multicenter, Open-Label, Phase 3, Randomized Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients with Relapsed/Refractory Nodal T Cell Lymphoma with T Follicular Helper Phenotype

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Neurofilaments As Serum Biomarkers of Brentuximabvedotin-Induced Peripheral Neurotoxicity in CD30 + Lymphoma Patients: A Prospective Single-Center Study

Impact of Front-Line Treatment Interim PET/CT in Peripheral T-Cell Lymphoma Patients' Survival: Experience of a Single Center

Comprehensive Geriatric Assessment in Diffuse Large B-Cell Lymphomas Patients Older Than 70 Years Old: Prospective Single-Center Experience

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Epigenetic loss of m 1 A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only